• Reviva Pharmaceuticals posted a net loss of $3.2 million, or $0.46 per share, for the three months ended March 31, 2026, narrowing from a $6.4 million loss a year earlier.
• Operating loss improved to $3.27 million as operating expenses fell to $3.27 million from $6.54 million in the prior-year quarter.
• Cash and cash equivalents climbed to $22.2 million as of March 31, 2026, up from $14.4 million at Dec. 31, 2025.
• Filed a U.S. composition-of-matter provisional patent application for a new form of brilaroxazine aimed at extending exclusivity potentially through 2046; expects FDA feedback in mid-2026 on using it in the RECOVER-2 Phase 3 trial and a future NDA.
• Patient enrollment for the RECOVER-2 registrational Phase 3 schizophrenia trial is expected to begin in Q3 2026; completed a March 2026 public equity offering raising gross proceeds of $10 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Reviva Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605131635PRIMZONEFULLFEED9719787) on May 13, 2026, and is solely responsible for the information contained therein.